In order to evaluate the potential use of ERK1/2 pathway inhibitors in ARMD treatment and to better understand the ocular side effects observed in cancer patients treated with such inhibitors, we disrupted ERK1/2 expression specifically in RPE cells of mice. Here, MAPK3 is linked to age-related macular degeneration.